Edwards Lifesciences (NYSE:EW) Hits New 52-Week High – Time to Buy?

Edwards Lifesciences Corporation (NYSE:EW) reached a new 52-week high on Tuesday . The company traded as high as $92.88 and last traded at $91.3310, with a volume of 3606234 shares traded. The stock had previously closed at $90.78.

Analyst Ratings Changes

Several brokerages recently issued reports on EW. BTIG Research lifted their target price on Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Monday, April 13th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price for the company in a research note on Wednesday, April 1st. Finally, TD Cowen reiterated a “buy” rating and issued a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $95.96.

Edwards Lifesciences Price Performance

The firm has a market cap of $52.59 billion, a PE ratio of 48.58, a PEG ratio of 2.28 and a beta of 0.87. The firm has a fifty day simple moving average of $84.66 and a two-hundred day simple moving average of $83.31. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 620 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $81.14, for a total transaction of $50,306.80. Following the sale, the vice president owned 40,411 shares of the company’s stock, valued at $3,278,948.54. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 81,038 shares of company stock worth $6,683,255. Company insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in EW. Norges Bank bought a new stake in Edwards Lifesciences during the fourth quarter worth approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after purchasing an additional 4,108,270 shares during the last quarter. Viking Global Investors LP bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $238,688,000. Marshall Wace LLP boosted its holdings in shares of Edwards Lifesciences by 66.1% in the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after purchasing an additional 2,359,128 shares during the period. Finally, Bank of America Corp DE increased its position in Edwards Lifesciences by 132.4% during the first quarter. Bank of America Corp DE now owns 3,883,419 shares of the medical research company’s stock valued at $310,984,000 after acquiring an additional 2,212,208 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.